CN102085337B - 一种用于治疗小儿哮喘的贴剂 - Google Patents
一种用于治疗小儿哮喘的贴剂 Download PDFInfo
- Publication number
- CN102085337B CN102085337B CN200910227111A CN200910227111A CN102085337B CN 102085337 B CN102085337 B CN 102085337B CN 200910227111 A CN200910227111 A CN 200910227111A CN 200910227111 A CN200910227111 A CN 200910227111A CN 102085337 B CN102085337 B CN 102085337B
- Authority
- CN
- China
- Prior art keywords
- parts
- patch
- asthma
- hours
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000006673 asthma Diseases 0.000 title abstract description 29
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title abstract description 8
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 3
- 244000140786 Brassica hirta Species 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 32
- 208000035756 Infantile asthma Diseases 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 244000184734 Pyrus japonica Species 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 238000012360 testing method Methods 0.000 abstract description 21
- 238000001467 acupuncture Methods 0.000 abstract description 11
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 241000471262 Ardisia japonica Species 0.000 abstract 1
- 235000017965 Asarum canadense Nutrition 0.000 abstract 1
- 235000011371 Brassica hirta Nutrition 0.000 abstract 1
- 235000000385 Costus speciosus Nutrition 0.000 abstract 1
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 241000606265 Valeriana jatamansi Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000014687 Zingiber zerumbet Nutrition 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 description 21
- 238000011282 treatment Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 208000000059 Dyspnea Diseases 0.000 description 14
- 206010013975 Dyspnoeas Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 206010011224 Cough Diseases 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗小儿哮喘的贴剂，包括药用组合物，其特征在于所述药用组合物采用以下主要组分和重量份用量：麻黄10-30份、白芥子10-30份、丁香1-15份、矮地茶15-45份、细辛5-20份、生姜10-30份。经临床试验，本发明的贴剂无任何不良反应，疗效显著，还发现病人经治疗后，其体质有明显增强，提示本品具有增强机体的免疫功能。说明用香麻寒喘贴贴敷穴位具有显著的治喘及增强哮喘患儿体质，预防哮喘病复发的作用。
Description
技术领域
本发明属于中药贴剂，具体涉及一种用于治疗小儿哮喘的贴剂。
背景技术
小儿哮喘、支气管炎是儿科临床常见多发病，不仅危害小儿健康，而且给家庭和社会造成巨大的经济负担。据资料报导，我国儿童哮喘患病率为0.5％～2％，个别地方高达5％，全国约有2～4千万患儿。现代医学认为支气管哮喘是一种由超敏反应引起的呼吸道高反应性疾病。在药物治疗方面强调根据病情需要，除使用解痉平喘药物外(对症治疗)，还应该结合使用抗气道过敏性炎症的药物(病因治疗)，糖皮质激素(GCS)是目前治疗哮喘的最有效药物，主要采用喷喉或雾化吸入。通过平喘和抗过敏炎症药物双管齐下的办法，以便达到迅速和持久的疗效，但GCS吸入的副作用是全身性，特别是对哮喘儿童，Nicolaizik研究认为哮喘儿童即使是短期吸入小剂量的GCS亦可引起肾上腺抑制，长期服用GCS可使哮喘儿童骨密度降低，使生长速率降低，由此GCS用于小儿哮喘的临床治疗受到了较大限制。
近年来，采用“冬病夏治”，敷贴疗法防治小儿哮喘，在全国各地广泛地开展。处方的组成，各地根据当地的情况，各有不同，贴药的方法及穴位选择，则异中有同，大都是将处方药材碾成粉末，用生姜汁调和成糊状，制成药饼，敷贴在百劳、膏肓、肺俞穴位，于炎热的三伏天敷贴。有一种叫敷贴发泡法，药物制作将生姜汁改为蜜调和成药饼，放在火上烘热，先用生姜擦穴位皮肤使之发热，病人感到刺痛为止，再将烘热药饼贴上，皮肤会发生水泡，局部感到热辣刺痛表示有效。这种方法，容易引起皮肤发炎感染，另外，发生水泡的皮肤对药物的吸收，将会受到影响。哮喘外治还有很多方法，如穴位埋藏疗法，用肠线埋藏穴位，这种方法疗效并不确切。针灸疗法治疗哮喘，小儿不易接受，难以配合。有人用挑四缝穴治小儿哮喘，痛苦难当。还有人制出中药背心和中药枕头防治哮喘，将传统的穴位敷贴疗法和香袋佩带疗法融合为一体，药物芳香温通，可由皮肤吸收和呼吸吸收，确有好处，但由于空气潮湿，或出汗，容易受潮，结块霉变，影响疗效。
发明内容
本发明的目的是提供一种使用方便、无副作用、疗效好，可增强机体的免疫功能的用于治疗小儿哮喘的贴剂。
实现上述发明目的采用的技术方案是：用于治疗小儿哮喘的贴剂，其药用组合物采用以下主要组分和用量(按重量份)：
麻黄10-30份、白芥子10-30份、丁香1-15份、矮地茶15～45份、细辛5～20份、生姜10-30份。
优选用量为：麻黄20份、白芥子20份、丁香3.3份、矮地茶33.3份、细辛10份、生姜20份。
本发明的贴剂中，麻黄具有发汗、利尿、镇咳、平喘、抗过敏、升高血压、兴奋中枢神经系统、解热、抗病毒及影响神经肌肉传递等作用。白芥子功效主治化痰逐饮、散结消肿、咳喘痰多、胸满胁痛、肢体麻木、关节肿痛、湿痰流注、阴疽肿毒、治喘咳宜敷贴背部肺俞、心俞、膈痰饮等。丁香，功效有暖胃、温肾，主治胃寒痛胀、呃逆、吐泻、痹痛、疝痛、口臭、牙痛。矮地茶，功效有止咳平喘，清利湿热，活血化瘀。细辛，功效有解表散寒，祛风止痛，通窍，温肺化饮。生姜的主要功效有散寒解表；降逆止呕；化痰止咳，主治风寒感冒、恶寒发热、头痛鼻塞、呕吐、痰饮喘咳、胀满、泄泻等。
基本制备方法：以上六味药经预处理后，加6倍量水蒸馏4小时，挥发油另置，药液及药渣备用；余药加水煎煮二次，第一次加8倍量水，煎煮2小时，滤过，药液备用；药渣再与提油后的药渣合并煎煮第二次，加6倍水量煎煮1小时，滤过。合并上述煎液及提挥发油后的药液，浓缩至相对密度约为1.20(80℃)的清膏，加乙醇使含醇量达50％，搅匀，静置24小时。取上清液，减压回收乙醇，浓缩至相对密度约为1.28(80℃)的稠膏，备用。将生橡胶100g切成条状，用压胶机压成网状胶片，去静电、放冷，浸入汽油中约24小时，使其充分溶胀，再移入配料锅内搅拌约3小时，依次加入松香80g、氧化锌80g、羊毛脂15g、凡士林15g、液体石蜡10g，混匀，加入上述清膏及挥发油，搅匀，经80目铜丝筛网滤过，进行涂膏，切段，盖衬，切块，即得。
用药方法和疗效
将本发明贴剂(香麻寒喘贴)分别贴主穴双侧肺俞(第3胸椎棘突下旁开1.5寸)和配穴双侧定喘(大椎穴旁开0.5寸)、双侧膏肓(第4胸椎棘突下旁开3寸)，一日贴1次，一次4～6小时。疗程为4天。
香麻寒喘贴可以缓解哮喘症状和寒饮停肺证候，其单项症状的疗效：香麻寒喘贴对喉中哮鸣，咳嗽，恶寒怕冷，鼻流清涕，痰液清稀等症状均有疗效，香麻寒喘贴对哮鸣症状有显著疗效，总有效率为94.68％。
本发明的主要特点：①是《内经》“冬病夏治”、“内病外治”理论的具体体现；②是在《张氏医通》“白芥子涂法”基础上改进而来；③属于采用现代工艺制成的一种橡胶膏类外用药；④应用中医脏腑与腧穴相关理论，选择与儿童支气管哮喘病(寒哮型)密切相关的重要穴位，进行贴药治疗，使药性效能通过皮毛腠理由表入里，循穴位经络的感传载运直达病所，发挥治疗作用；⑤剂型选择与儿童用药特点相结合，制剂由过去外敷散剂改为橡胶膏剂，利用现代透皮吸收技术，既保证了药效，又方便使用，勿需打针服药，患儿容易接受，充分考虑了儿童用药的特点。经临床试验，本发明的贴剂无任何不良反应，疗效显著，还发现病人经治疗后，其体质有明显增强，提示本品具有增强机体的免疫功能。说明用香麻寒喘贴贴敷穴位具有显著的治喘及增强哮喘患儿体质，预防哮喘病复发的作用。
具体实施方式
本发明贴剂(药品名称为香麻寒喘贴)可通过试验例来说明其有益效果，包括毒理试验和主要药效学试验。
毒理试验
(1)急性毒性试验：将香麻寒喘贴每次以小儿外贴量的6倍量贴家兔完整和破损皮肤，多次给药均无刺激，对豚鼠皮肤无过敏反应，且未见任何毒副反应。
(2)长期毒性试验：将香麻寒喘贴每次以小儿外贴量的2倍、5倍、10倍量，分别贴于脱去毛的家兔背部(双肺投影背部)，每次贴4小时，每日贴1次，连续2周。对其血象、肺、肝、肾功能观察，未发现有毒性作用；经病理切片未发现心、肝、脾、肺、肾等器官有毒性损害。故提示临床推荐用药剂量使用安全。
主要药效学试验
一、动物试验
(1)对氨水引咳小鼠和枸橡酸引咳豚鼠均可明显延长发生咳嗽的潜伏期，减少咳嗽次数，提示本品具有止咳作用。
(2)能显著促进小鼠气管排泌酚红，增加大鼠气管的排痰量，提示本品具有明显的祛痰作用。
(3)对乙酰胆碱和组胺混合引喘豚鼠可明显延长哮喘发生的时间，提示本品具有平喘作用。
(4)对巴豆油致小鼠耳肿胀具有明显的抑制作用，对2.4-二硝基氯苯所致小鼠迟发型皮肤超敏反应具有明显的抑制作用，对环磷酰胺所致免疫功能低下小鼠具有促进血清溶血抗体形成，提高巨噬细胞吞噬功能的作用，提示本品具有抗炎、提高免疫功能的作用。
(5)以小儿外贴量的2倍、5倍、10倍量，分别贴于脱去毛的家兔背部(双肺投影背部)，每次贴4小时，每日贴1次，连续2周。对其血象、肺、肝、肾功能观察，未发现有毒性作用；经病理切片未发现心、肝、脾、肺、肾等器官有毒性损害。故提示临床推荐用药剂量使用安全。
二、临床试验
经用香麻寒喘贴治疗小儿哮喘120例疗效观察，
1、试验目的：验证香麻寒喘贴辅助治疗儿童支气管哮喘寒饮停肺证的有效性，初步评价香麻寒喘贴临床应用的安全性。
2、观测指标：(1)人口学资料：①性别；②年龄；③身高；④体重。(2)主要疗效性指标：①中医证候：主症(喘息、喉中哮鸣、咳嗽)；次症(恶寒怕冷、鼻流清涕、咯痰清稀、四肢欠温、面色淡白)；异常舌脉。②肺功能：PEFR。(3)次要疗效指标：①周围血嗜酸粒细胞计数。②血清IgE。(4)安全性指标：①可能出现的不良反应症状。②一般体检项目：体温、安静时心率、呼吸、血压等。③血常规、尿常规、便常规、心电图和肝功能GPT、肾功能BUN和Cr。
3、试验总体设计
本项试验采用平行组设计、分层区组随机、双盲加载试验、多中心临床研究的方法。所选病证为儿童支气管哮喘发作期寒饮停肺证，按1∶1为试验组和对照组两组，受试者分别为120例，共240例。
4、试验人群
符合儿童支气管哮喘寒饮停肺证中西医诊断、辨证标准、年龄在3岁～14岁之间、发病本次在48小时以内、病情属于轻中度者。
5、给药方案
氨茶碱：两组均用。每次4～6mg/Kg，q.8.h口服。最大剂量不超过200mg/次。香麻寒喘贴及其模拟药：两组均外用。使用方法：分别贴主穴双侧肺俞和配穴双侧定喘、双侧膏肓，每日贴1次，每次4～6个小时。疗程：4天。合并用药规定：对于合并各种病原微生物感染者，可分别加用病毒唑、红霉素类治疗，必要时应补充液体入量。但不能加用止咳化痰、抗组胺、糖皮质激素类西药以及同类中药。
6、评价标准
(1)疾病疗效评定标准：①临床控制：哮喘症状完全缓解，即使偶有轻度发作不需用药即可缓解。PEFR增加量＞35％，或治疗后PEFR＞＝80％预计值。PEFR昼夜波动＜20％。②显效：哮喘发作较治疗前明显减轻，PEFR增加量范围25％～35％，或治疗后PEFR达到预计值的60％～＜80％，PEFR昼夜波动＜20％。③好转：哮喘症状有所减轻，PEFR增加量范围15％～＜25％。④无效：临床症状和PEFR测定值无改善或反而加重。
(2)中医证候疗效评定标准：①临床痊愈：证候计分值减少率＞95％。②显效：证候计分值减少率＞70％～95％。③进步：证候计分值减少率30％～70％。④无效：证候计分值减少率＜30％。
(3)安全性评价标准：①一级：安全，无任何不良反应。②二级：比较安全，如有不良反应，不需做任何处理可继续给药。③三级：有安全性问题，有中等程度的不良反应，做处理后可继续给药。④四级：因不良反应中止试验。
7、统计方法
(1)、对计量数据，采用t检验、t’检验、秩和检验、方差分析、协方差分析等方法。
(2)、对计数数据，采用四格表X2检验、Yates连续校正X2检验、Fisher精确概率法、多表格X2检验等方法。
(3)、对等级数据，采用符号秩和检验、秩和检验。
8、受试者入组情况及各组人口学资料
按试验计划，五家参试单位共入选240例病例。其中，脱落4例，剔除2例。两组病例来源情况门诊208例，病房32例；两组在基线点，其性别、年龄、身高、体重、病程、病情、生命体征、中医证候等资料比较，差异均无显著性意义，具有可比性。
9、各组疗效结果
试验结果表明，两组疾病疗效比较，ITT分析试验组疾病控显率为78.81％，总有效率为92.37％，对照组疾病控显率为39.17％，总有效率为66.67％；PP分析试验组疾病控显率为80.17％，总有效率为93.97％，对照组疾病控显率为39.83％，总有效率为67.8％，两组比较均有显著性差异。
ITT分析试验组中医证候控显率为56.78％，总有效率为92.37％，对照组中医证候控显率为18.33％，总有效率为68.33％，PP分析试验组中医证候控显率为57.76％，总有效率为93.97％，对照组中医证候控显率为18.64％，总有效率为69.49％，两组比较均有显著性差异。
主要观察指标的改善情况，两组各中医证候指标治疗前后证候总计分和、主症计分和的变化和改善情况，两组患者PEFR治疗前后差值和增加量组间比较，PP分析和ITT分析差异均有非常显著性意义；单项症状的改善情况自身比较，差异均有非常显著性意义；且除面色淡白、四肢欠温外的全部证候指标的组间比较，差异也均有显著性意义。
10、各组安全性结果
试验中，两组各有1例病例应用香麻寒喘贴后出现局部皮肤红痒、皮疹，此外无其他不良事件发生。实验室检查未发现有与试验药物有关的改变。
11、结论
香麻寒喘贴对儿童支气管哮喘寒饮停肺证具有治疗作用，不良反应的发生率低，安全性好，具有临床使用价值。
以下是本发明提供的贴剂实施例，其用药量为1000贴中的药用组合物。
实施例1
麻黄100克、白芥子101克、丁香10克、矮地茶450克、细辛200克、生姜300克。
实施例2
麻黄200克、白芥子300克、丁香150克、矮地茶150克、细辛50克、生姜100克。
实施例3
麻黄200克、白芥子200克、丁香33克、矮地茶333克、细辛100克、生姜200克。
Claims (2)
1.一种用于治疗小儿哮喘的贴剂，包括药用组合物，其特征在于所述药用组合物采用以下原料药和重量份用量：
麻黄10-30份、白芥子10-30份、丁香1-15份、矮地茶15～45份、细辛5～20份、生姜10-30份；
以上六味药经预处理后，加6倍量水蒸馏4小时，挥发油另置，药液及药渣备用；余药加水煎煮二次，第一次加8倍量水，煎煮2小时，滤过，药液备用；药渣再与提油后的药渣合并煎煮第二次，加6倍水量煎煮1小时，滤过；合并上述煎液及提挥发油后的药液，浓缩至80℃时的相对密度为1.20的清膏，加乙醇使含醇量达50％，搅匀，静置24小时；取上清液，减压回收乙醇，浓缩至80℃时的相对密度为1.28的稠膏，备用；将生橡胶100g切成条状，用压胶机压成网状胶片，去静电、放冷，浸入汽油中约24小时，使其充分溶胀，再移入配料锅内搅拌约3小时，依次加入松香 80g、氧化锌80g、羊毛脂15g、凡士林15g、液体石蜡10g，混匀，加入上述清膏及挥发油，搅匀，经80目铜丝筛网滤过，进行涂膏，切段，盖衬，切块，即得。
2.根据权利要求1所述的用于治疗小儿哮喘的贴剂，其特征在于所述组分的重量份用量为：麻黄20份、白芥子20份、丁香3.3份、矮地茶33.3份、细辛10份、生姜20份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910227111A CN102085337B (zh) | 2009-12-07 | 2009-12-07 | 一种用于治疗小儿哮喘的贴剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910227111A CN102085337B (zh) | 2009-12-07 | 2009-12-07 | 一种用于治疗小儿哮喘的贴剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102085337A CN102085337A (zh) | 2011-06-08 |
| CN102085337B true CN102085337B (zh) | 2012-10-24 |
Family
ID=44097498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910227111A Expired - Fee Related CN102085337B (zh) | 2009-12-07 | 2009-12-07 | 一种用于治疗小儿哮喘的贴剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102085337B (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446414B (zh) * | 2013-08-30 | 2014-10-29 | 山东翔宇健康制药有限公司 | 一种香麻寒喘贴及其制备工艺 |
| CN103623389B (zh) * | 2013-12-26 | 2016-01-13 | 张秀美 | 一种治疗风寒型小儿支气管炎的中药组合物 |
| CN104740581B (zh) * | 2015-04-13 | 2018-04-06 | 翔宇药业股份有限公司 | 一种香麻寒喘贴的应用及其检测方法 |
| CN105267915A (zh) * | 2015-10-19 | 2016-01-27 | 翔宇药业股份有限公司 | 一种可用于化痰止咳的贴剂及其制备工艺 |
| CN107670004A (zh) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | 一种用于哮喘、支气管炎的药物制剂及其制备方法 |
| CN107670005A (zh) * | 2017-10-13 | 2018-02-09 | 翔宇药业股份有限公司 | 香麻寒喘贴的制备工艺及其检测方法 |
| CN108434413A (zh) * | 2018-03-22 | 2018-08-24 | 翔宇药业股份有限公司 | 香麻寒喘贴及其应用和质量检测方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176115C (zh) * | 2002-02-07 | 2004-11-17 | 中国石油天然气股份有限公司 | 茂金属烯烃聚合主催化剂的合成方法 |
| CN101332290B (zh) * | 2008-08-05 | 2010-12-08 | 赵桂香 | 一种治疗慢性支气管炎的中药组合物 |
-
2009
- 2009-12-07 CN CN200910227111A patent/CN102085337B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176115C (zh) * | 2002-02-07 | 2004-11-17 | 中国石油天然气股份有限公司 | 茂金属烯烃聚合主催化剂的合成方法 |
| CN101332290B (zh) * | 2008-08-05 | 2010-12-08 | 赵桂香 | 一种治疗慢性支气管炎的中药组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102085337A (zh) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102085337B (zh) | 一种用于治疗小儿哮喘的贴剂 | |
| CN104189554A (zh) | 一种治疗小儿热性哮喘的中药贴及其制备方法 | |
| CN105497261A (zh) | 一种外用贴剂基质及该基质制成的外用贴剂和助眠贴 | |
| CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
| CN103735610A (zh) | 用于缓解体力疲劳的颗粒剂 | |
| CN101032598B (zh) | 化痰止咳平喘养生酒 | |
| CN103028060B (zh) | 用于治疗婴幼儿急性湿疹的中药组合物及其制备方法 | |
| CN105267915A (zh) | 一种可用于化痰止咳的贴剂及其制备工艺 | |
| CN104958727B (zh) | 一种治疗儿童哮喘缓解期的中药组合物及其应用 | |
| CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
| CN104288303A (zh) | 治疗心脑血管疾病的中药 | |
| CN104740581B (zh) | 一种香麻寒喘贴的应用及其检测方法 | |
| CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
| CN102048956A (zh) | 一种药酒 | |
| CN100364587C (zh) | 一种治疗慢性支气管炎、支气管哮喘的取穴贴敷药物及其配制方法 | |
| CN104940304A (zh) | 一种用于离子导入疗法的治疗儿童哮喘缓解期的敷贴 | |
| CN102949509A (zh) | 一种用于清肺止咳的纯中药保健糖浆剂及其制备方法 | |
| CN100406035C (zh) | 一种治疗腰椎间盘突出症的中药制剂 | |
| CN107335011A (zh) | 治疗癌性疼痛的外用中药复方制剂 | |
| CN105012819A (zh) | 一种用于支气管哮喘的药物制剂 | |
| CN107875256A (zh) | 一种治疗失眠症的壮药穴位贴敷药贴及其制作方法 | |
| CN104906207A (zh) | 一种预防慢性阻塞性肺疾病发作的外治药物及其制备方法 | |
| CN105726849B (zh) | 一种用于治疗糖尿病后抑郁症的中药 | |
| CN104435635B (zh) | 一种治疗绝经后冠心病中药组合物 | |
| CN106237156A (zh) | 一种治疗胃癌的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHANGSHA CHENGRUN FOOD TECHNOLOGY DEVELOPMENT CO., Free format text: FORMER OWNER: LUO QIAN Effective date: 20140425 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410007 CHANGSHA, HUNAN PROVINCE TO: 410000 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140425 Address after: 410000 Hunan province Changsha Kaifu District, Deya Road No. 1420 District 33 building room 505 Golden Sail Patentee after: CHANGSHA CHENGRUN FOOD TECHNOLOGY DEVELOPMENT CO., LTD. Address before: Labor Road 410007 Hunan province Changsha Yuhua District, No. 174 Fu Le Cannes 8 Building 1 unit 1201 room Patentee before: Luo Qian |
|
| ASS | Succession or assignment of patent right |
Owner name: LUO QIAN Free format text: FORMER OWNER: CHANGSHA CHENGRUN FOOD TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20140702 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410000 CHANGSHA, HUNAN PROVINCE TO: 410007 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140702 Address after: Labor Road 410007 Hunan province Changsha Yuhua District, No. 174 Fu Le Cannes 8 Building 1 unit 1201 room Patentee after: Luo Qian Address before: 410000 Hunan province Changsha Kaifu District, Deya Road No. 1420 District 33 building room 505 Golden Sail Patentee before: CHANGSHA CHENGRUN FOOD TECHNOLOGY DEVELOPMENT CO., LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170321 Address after: 410014 Hunan province Changsha Kaifu District, Deya Road No. 1420 District 33 building room 505 Golden Sail Patentee after: Changsha Fuqin Hall Chinese New Technology Development Co Ltd Address before: Labor Road 410007 Hunan province Changsha Yuhua District, No. 174 Fu Le Cannes 8 Building 1 unit 1201 room Patentee before: Luo Qian |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171116 Address after: 276000 Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Province, No. 30 Patentee after: Xiang Yu Pharmaceutical limited company Address before: 410014 Hunan province Changsha Kaifu District, Deya Road No. 1420 District 33 building room 505 Golden Sail Patentee before: Changsha Fuqin Hall Chinese New Technology Development Co Ltd |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20181207 |